For the management of osteoarthritis (OA) of the knee…

CHRONIC OA PAIN

Meet Your Match

ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) is the first and only approved treatment for OA knee pain utilizing extended-release microsphere technology.

SEE HOW IT WORKS

WHY ZILRETTA?

Explore ZILRETTA and learn why it may be right for your patients experiencing OA knee pain.

ENGINEERED

Novel microsphere formulation is composed of triamcinolone acetonide (TA) embedded in a biodegradable PLGA matrix1,2

ZILRETTA is not interchangeable with other formulations of injectable triamcinolone acetonide

ENDURING

In a pharmacokinetic study, quantifiable TA concentrations were maintained in the synovial fluid out to 12 weeks3*

PROVEN

There was statistically significant reduction in average daily pain intensity with ZILRETTA vs saline control at Week 12 (P<0.0001)4

GENERALLY SAFE

The overall incidence and nature of adverse reactions were similar to saline control

The most commonly reported treatment-emergent adverse reactions (incidence ≥1%) in clinical studies included sinusitis, cough, and contusions

*The clinical relevance of this synovial fluid information is unknown.
PLGA=poly(lactic-co-glycolic acid).

Indication and Select Important Safety Information

Indication

ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.

Limitation of Use: ZILRETTA is not intended for repeat administration.*

Contraindication

ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids, or any components of the product.

Please see full Important Safety Information below



WANT TO KNOW MORE ABOUT ZILRETTA?

Get more information on ZILRETTA in your office or your inbox. Schedule a rep visit or sign up for email updates to be sure you have the latest information on new developments and support for you, your staff, and your patients.

REQUEST A REP/EMAIL SIGN-UP

Provider Locator and ZSource toolkit

Provider Locator

Expand your sphere of influence by signing up to have your practice featured in the Provider Locator on our patient website. The locator will connect patients with nearby healthcare providers who have experience using ZILRETTA.

Join the Locator

ZSource Toolkit

Get access to a variety of resources and tools to let your patients know that ZILRETTA is available in your practice.

Get Access to ZSource

GET YOUR PATIENTS STARTED

We work within your established process and provide comprehensive access support at every step with FlexForwardSM

SEE HOW IT WORKS

Indication and Important Safety Information

Indication

ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.

Limitation of Use: ZILRETTA is not intended for repeat administration.*

Contraindication

ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids, or any components of the product.

Warnings and Precautions

  • Intra-articular Use Only: ZILRETTA has not been evaluated and should not be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. Serious events have been reported with epidural and intrathecal administration of corticosteroids and none are approved for this use. ZILRETTA should not be considered safe for epidural or intrathecal administration.
  • Hypersensitivity Reactions: Rare instances of anaphylaxis, including serious cases, have occurred in patients with hypersensitivity to corticosteroids.
  • Joint Infection and Damage: A marked increase in pain accompanied by local swelling, restriction of joint motion, fever, and malaise are suggestive of septic arthritis. Examine joint fluid to exclude a septic process. If diagnosis is confirmed, institute appropriate antimicrobial therapy. Avoid injecting corticosteroids into a previously infected or unstable joint. Intra-articular administration may result in damage to joint tissues.
  • Increased Risk of Infections: Infection with any pathogen in any location of the body may be associated with corticosteroid use. Corticosteroids may increase the susceptibility to new infection and decrease resistance and the ability to localize infection.
  • Alterations in Endocrine Function: Corticosteroids can produce reversible hypothalamic-pituitary-adrenal axis suppression, with potential for adrenal insufficiency after withdrawal of treatment, which may persist for months. In situations of stress during that period, institute corticosteroid replacement therapy.
  • Cardiovascular and Renal Effects: Corticosteroids can cause blood pressure elevation, salt and water retention, and increased potassium excretion. Monitor patients with congestive heart failure, hypertension, and renal insufficiency for edema, weight gain, and electrolyte imbalance. Dietary salt restriction and potassium supplementation may be needed.
  • Increased Intraocular Pressure: Corticosteroid use may be associated with increased intraocular pressure. Monitor patients with elevated intraocular pressure for potential treatment adjustment.
  • Gastrointestinal Perforation: Corticosteroid administration may increase risk of gastrointestinal perforation in patients with certain GI disorders and fresh intestinal anastomoses. Avoid corticosteroids in these patients.
  • Alterations in Bone Density: Corticosteroids decrease bone formation and increase bone resorption. Special consideration should be given to patients with or at increased risk of osteoporosis prior to treatment.
  • Behavior and Mood Disturbances: Corticosteroids may cause adverse psychiatric reactions. Prior to treatment, special consideration should be given to patients with previous or current emotional instability or psychiatric illness. Advise patients to immediately report any behavior or mood disturbances.

Adverse Reactions

The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis, cough, and contusions.

Please see full Prescribing Information.

*The efficacy and safety of repeat administration of ZILRETTA have not been evaluated.

References:

  1. Bodick N, Lufkin J, Willwerth C, et al. An intra-articular, extended-release formulation of triamcinolone acetonide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial. J Bone Joint Surg Am. 2015;97(11):877-888.
  2. Makadia HK, Siegel SJ. Poly Lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377-1397.
  3. Kraus VB, Conaghan PG, Aazami HA, et al. Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). Osteoarthr Cartilage. 2018;26(1):34-42.
  4. Conaghan PG, Hunter DJ, Cohen SB, et al. Effects of a single intra-articular injection of a microsphere formulation of triamcinolone acetonide on knee osteoarthritis pain: a double-blinded, randomized, placebo-controlled, multinational study. J Bone Joint Surg Am. 2018;100(8)666-677.